23andMe Holding Co. (ME)
After hours:
| Previous Close | 0.4121 |
| Open | 0.4058 |
| Bid | 0.4092 x 800 |
| Ask | 0.4133 x 800 |
| Day's Range | 0.4020 - 0.4240 |
| 52 Week Range | 0.3500 - 2.0300 |
| Volume | |
| Avg. Volume | 5,710,377 |
| Market Cap | 201.986M |
| Beta (5Y Monthly) | 1.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4000 |
| Earnings Date | May 23, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.31 |
The GuardianGenetic testing company 23andMe investigated over hack that hit 7m users
Data watchdogs in UK and Canada to look at whether there were enough safeguards on personal information
GlobeNewswire23andMe Launches New Genetic Report on Bipolar Disorder
Provides 23andMe+ Premium members with insight into their likelihood of developing the serious mental health illness based on thousands of genetic variantsSOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the co
- GlobeNewswire
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
Study aims to fill research gap and empower people through access to information about their healthSUNNYVALE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance (Alliance), the largest nonprofit organization dedicated to ending colorectal cancer, announced a collaboration to help advance research on colorectal cancer in the Black/African American community. The Genetic In
